CI Investments Inc. Has $45.78 Million Stock Position in Stryker Corporation $SYK

CI Investments Inc. boosted its position in shares of Stryker Corporation (NYSE:SYK) by 6.1% in the 1st quarter, HoldingsChannel reports. The firm owned 139,310 shares of the medical technology company’s stock after buying an additional 8,043 shares during the period. CI Investments Inc.’s holdings in Stryker were worth $45,776,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth approximately $26,000. Sankala Group LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG acquired a new stake in Stryker during the 4th quarter valued at $28,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SYK shares. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a report on Friday, May 1st. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Finally, Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $392.52.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Stryker Stock Down 1.6%

Shares of SYK opened at $313.89 on Wednesday. The business’s fifty day moving average price is $313.79 and its two-hundred day moving average price is $336.20. The firm has a market capitalization of $120.33 billion, a price-to-earnings ratio of 36.33, a PEG ratio of 2.04 and a beta of 0.77. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the firm earned $2.84 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts predict that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.